20384 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Non condensed pyridines; Hydrogenated derivatives thereof; Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
Quantitative Method of Determining a Mental Status Based on DRD1 and/or DRD5, and its Application Thereof
#2GENE THERAPY FOR AADC DEFICIENCY
#3CAREBASTINE SALT AND USE OF SAME
#4PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INSOMNIA
#5Nasal Spray for Phosphodiesterase Inhibitors
#6OCULAR TREATMENTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
#7Vaginal Drug Delivery Device
#8HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY
#9METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
#10A NANOFORMULATION FOR GLIOMA TREATMENT AND PROCESS FOR ITS PREPARATION THEREOF
#11GENE THERAPY FOR AADC DEFICIENCY
#12Methods and Compositions for Treating Psychotic Disorders
#13SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY
#14ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND
#15TREATMENT OF SCHIZOPHRENIA USING BETA-CARYOPHYLLENE AND CB2 RECEPTOR AGONISTS
#16Wearable device for managing alcohol-driven violence
#17RADIATION SENSITIVITY ENHANCING COMOPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT
#18DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF
#19NOVEL PFAR-INHIBITING COMPOUNDS
#20Compositions and methods for inhibition of SARS-CoV-2 viral infections
#21SUSTAINED-RELEASE LIPID COMPOSITION AND PREPARATION METHOD THEREFOR
#22METHOD FOR PRODUCING ORAL DISINTEGRATING FILM COMPRISING POORLY SOLUBLE DRUG
#23METHODS AND SYSTEMS FOR DETECTING PSYCHOTIC DISORDERS ASSOCIATED WITH SEROTONIN RECEPTOR DEFICIENCIES
#24Methods and Compositions for Treating Psychotic Disorders
#25Gene therapy for AADC deficiency
#26RADIATION SENSITIVITY ENHANCING COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT
#27COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE
#28METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
#29NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER
#30DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF
#31Treatment of schizophrenia using beta-caryophyllene and CB2 receptor agonists
#32METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
#33EBASTINE TOPICAL COMPOSITION
#34METHOD FOR MODIFYING THE THERAPEUTIC EFFECTS OF DRUGS
#35Use of Sigma-1 receptor agonist compounds
#36Risperidone biodegradable implant
#37Self-Emulsifying Compositions of CB2 Receptor Modulators
#38METHOD OF TREATING SCHIZOPHRENIA
#39Gene therapy for AADC deficiency
#40Preservative-free prochlorperazine nasal spray for migraine therapy
#41Salts of active ingredients with polymeric counterions
#42USE OF WATER-SOLUBLE POLYMERS BASED ON N-VINYLPYRROLIDONE AND ACRYLIC ACID AS PHARMACEUTICAL ADJUVANTS
#43METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
#44Ocular treatments for neurological and neuropsychiatric disorders
#459-OH-risperidone controlled release composition
#46Antihistamine for use in treatment of breast cancer
#47Drug-containing PLA implants and methods of use thereof
#48Drug-containing implants and methods of use thereof
#49Preparation Method of Drug-Containing Sustained Release Microparticles
#50Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer
#51Prescription of intravenous medication for blocking heroin or morphine intoxication path and using thereof
#52Methods and compositions for treating infection
#53Methods of treating posttraumatic stress disorder with acamprosate salts
#54Drug-containing implants and methods of use thereof
#55Use of Sigma-1 receptor agonist compounds
#56Pharmaceutical microemulsion immobilized in a thin polymer matrix and methods of making them
#57COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED SYSTEMS
#58Pharmacological treatment of obsessive-compulsive disorder
#59COMPOSITIONS OF SMALL MOLECULE THERAPEUTICS
#60PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES
#61METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
#62Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical
#63ARRANGEMENT OF SPECIFIC ANTIDOTES WITH ALLOPATHIC MEDICINAL PREPARATIONS IN GENERAL SECONDARY PACKAGE
#64Device and method for sustained release of antipsychotic medications
#65METHODS AND COMPOSITIONS FOR TREATING INFECTION
#66Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#67Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#68Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#69Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#70Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#71Acamprosate formulations, methods of using the same, and combinations comprising the same
#72PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES
#73Pharmaceutical Compositions Comprising Ebastine and Fluticasone
#74Method for improving water solubility of slightly soluble substance
#75IN VIVO SCREENING METHOD OF THERAPEUTIC AGENT FOR MEMORY/LEARNING DYSFUNCTIONS BY SCHIZOPHRENIA
#76Synergistic Combination Therapy
#77Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
#78TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTRATION OF TIROFIBAN
#79Compositions and methods for the treatment of catatonia
#80Acamprosate formulations, methods of using the same, and combinations comprising the same
#81Acamprosate formulations, methods of using the same, and combinations comprising the same
#82Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#83Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#84COMBINED THERAPIES OF ANTIPSYCHOTIC DRUGS AND TETRACYCLINES IN THE TREATMENT OF PSYCHIATRIC DISORDERS
#85Combination of pimavanserin and risperidone for the treatment of psychosis
#86Risperidone-containing PLA:PGA implants and methods of use thereof
#87Synergistic Combination Therapy
#88PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES
#89Compositions and methods for treating parkinson's disease
#90METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER
#91Therapeutic or prophylactic agent for dyskinesia
#92TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTRATION OF TIROFIBAN
#93PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES
#94METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL
#95USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
#96COMBINED THERAPIES OF ANTIPSYCHOTIC DRUGS AND TETRACYCLINES IN THE TREATMENT OF PSYCHIATRIC DISORDERS
#97Compositions and methods for alleviating depression or improving cognition
#98Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
#99Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
#100Compositions Comprising Melperone
#101Compositions Comprising Melperone and Controlled-Release Dosage Forms
#102ACUTE TREATMENT OF HEADACHE WITH PHENOTHIAZINE ANTIPSYCHOTICS
#103PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES
#104SOLID ORAL FORMS OF EBASTINE
#105Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant
#106COMBINATION OF SABCOMELINE WITH A NEUROLEPTIC AGENT TO TREAT PSYCHOTIC DISORDERS
#107Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone
#108NEW USE OF ILOPERIDONE
#109Acute Treatment of Headache with Phenothiazine Antipsychotics
#110COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS
#111ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS
#112Sabcomeline Alone or Combined with a Mood Stabilising or Antimanic Agent to Treat Bipolar Disorders
#113NEW USE OF ILOPERIDONE
#114Treatment Of Cognitive Impairment Using A Selective Dopamine D1 Receptor Agonist
#115Combination of Sabcomeline with a Neuroleptic Agent to Treat Psychotic Disorders
#116Clozapine and Cocaine Effects on Dopamine and Serotonin Release in Nucleus Accumbens During Psychostimulant Behavior and Withdrawal
#117Calcium channel blockers
#118In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
#119Therapeutic combinations for the treatment or prevention of psychotic disorders
#120New use of iloperidone
#121Acute treatment of headache with phenothiazine antipsychotics
#122Drug-containing implants and methods of use thereof
#123Rapidly disintegrating tablet and process for producing the same
#124Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
#125Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features